Wightman Joins ClinPhone To Help Trial Management Specialist Develop New Markets
- February 25, 2002
ClinPhone Group, the successful specialist provider of electronic trial management solutions for the pharmaceutical industry, is hoping to maintain its impressive growth with the appointment of Kevin Wightman as Business Development Director for Late Phase and Emerging Services.
Wightman (37) will be responsible for taking the company's services to a wider customer base in a variety of innovative ways and overseeing consequent growth into existing or new markets.
He graduated in Chemistry and Pharmacology at Nottingham University in 1985, joining the pharmaceutical industry initially as a Medical Representative. After two years working in sales, he joined Glaxo and spent the next 10 years working in a variety of roles involving regulatory, clinical and training work.
During this period he also spent two years on secondment in Australia and also worked on international projects in the United States and in Japan, most notably as an International Study Team Leader for the flu drug Relenza.
He moved to Australia in 1997 to join Quintiles as its Clinical Operations Manager for Southern Australia. He moved to the company's UK operation in 2000 and worked in The Lewin and Innovex teams in Business Development prior to joining ClinPhone in January.
"This is a new role for ClinPhone and represents a fascinating opportunity to take our services and technologies into new arenas in the pharmaceutical and biotechnology industries," he commented.
The ClinPhone Group now employs around 250 people worldwide. It retains its global headquarters in Nottingham in the United Kingdom, but has three facilities in the United States, in New Jersey, Chicago and San Francisco and a central European office in Brussels, Belgium.